More than 10% of the population in Europe and North America suffer from IgE-associated allergy to grass pollen. In this article, we describe the development of a vaccine for grass pollen allergen-specific immunotherapy based on two recombinant hypoallergenic mosaic molecules, designated P and Q, which were constructed out of elements derived from the four major timothy grass pollen allergens: P...

Worldwide more than 200 million individuals are allergic to group 1 grass pollen allergens. We have used the major timothy grass pollen allergen Phl p 1, which cross-reacts with most grass-, corn-, and monocot-derived group 1 allergens to develop a generally applicable strategy for the production of hypoallergenic allergy vaccines. On the basis of the experimentally determined B cell epitopes o...

Background Immunotherapy for allergic rhinitis with/without conjunctivitis (AR/C) may exhibit different efficacy characteristics in patients with multiple allergen sensitizations than monosensitized patients. It has been considered that monosensitized patients may benefit more from immunotherapy than polysensitized patients. Evidence from randomized, blinded, placebo-controlled trials of Timoth...

Differences in nutrient content between different grass hay varieties are much smaller than differences between legumes and grasses (Table 1). Cool-season grasses (grown in temperate climates) include timothy, orchardgrass, fescue and annual ryegrass. Warm-season grasses (adapted to tropical and subtropical regions, like Florida) include Coastal bermudagrass, Tifton-85 bermudagrass, and bahiagr...

Background Seasonal allergic rhinitis/rhinoconjunctivitis symptoms are dependent on pollen exposure and may impact the observed treatment effect of drugs used to treat seasonal allergic rhinitis. We conducted a post-hoc analysis to investigate the impact of pollen exposure on the overall magnitude of the recorded immunotherapy treatment effect across multiple seasons and trials of Timothy grass...

Background The effect of MK-7243 (2800 BAU/75,000 SQ [~15 μg of Phleum pratense p 5], Merck/ALK-Abelló), a sublingual Timothy grass immunotherapy tablet, has been evaluated in several randomized, placebo-controlled, double-blind trials; three of these trials were conducted in adults and children in North America (the United States and Canada) who have allergic rhinitis with or without conjuncti...

Parallel to experimental immunological studies we performed computer simulations of the Phl p 6 allergen from timothy grass (Phleum pratense) pollen employing the Austrian Grid’s [1] infrastructure. The molecular dynamics studies were carried out for up to 40ns simulation time investigating the stability of the allergen. Additionally the reaction of the allergen to drastic sequence modification...

Grass pollen belong to the most important allergen sources involved in the elicitation of allergic asthma. We have isolated cDNAs coding for Bermuda grass (Cynodon dactylon) and timothy grass (Phleum pratense) pollen allergens, belonging to a family of pectin-degrading enzymes (i.e., polygalacturonases). The corresponding allergens, termed Cyn d 13 and Phl p 13, represent glycoproteins of appro...